New drug TB-500 aims to improve blood vessel health in heart disease patients
NCT ID NCT07487363
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing an experimental drug called TB-500 in 80 adults with stable atherosclerotic cardiovascular disease. The main goal is to see if the drug is safe and tolerable. Researchers will also measure changes in blood vessel function and inflammation as early signs of potential benefit.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TB-500 (a fragment of thymosin beta 4)
What this could lead to
If it works, this could point toward a new treatment to improve blood vessel function and reduce inflammation in people with stable heart disease.
What could go wrong
This is an early phase 1/2 trial with only 80 participants, so it is primarily testing safety. It may not show clear benefit, and the drug could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOTHELIAL DYSFUNCTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Shenzhen Hospital
RECRUITINGShenzhen, Guangdong, 518036, China
Contact Phone: •••-•••-•••• Email: •••••@•••••